Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05525338
Other study ID # 202000251
Secondary ID 2020-001737-13NL
Status Recruiting
Phase Phase 4
First received
Last updated
Start date March 23, 2022
Est. completion date December 31, 2026

Study information

Verified date May 2024
Source University Medical Center Groningen
Contact M.B. Muntinghe-Wagenaar, Msc
Phone +31503616161
Email adaptalec@umcg.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The ADAPT ALEC randomized controlled trial (RCT) is performed in patients with Anaplastic Lymphoma Kinase (ALK) positive non-small cell lung cancer (NSCLC). The RCT will compare the use of Therapeutic Drug Monitoring (TDM) and dose increases if alectinib 35 ng/Ml (arm A) with standard of care (arm B).


Description:

The ADAPT ALEC trial is a phase IV, RCT in patients with ALK positive NSCLC treated with alectinib. A longer median progression free survival (mPFS) is expected in patients treated with standard dose alectinib when minimum plasma concentrations (Cmin) of alectinib exceed 435 ng/mL. The ADAPT ALEC trial will investigate whether using therapeutic drug monitoring (TDM) and increasing the dose of alectinib in patients with Cmin <435 ng/mL, will raise the mPFS. We will compare mPFS in the subgroup of patients with an alectinib Cmin <435 ng/mL using TDM and dose increases (arm A) to fixed dosing/standard of care (arm B).


Recruitment information / eligibility

Status Recruiting
Enrollment 196
Est. completion date December 31, 2026
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with locally advanced or metastatic NSCLC (stage IIIB to stage IV by AJCC 8th) - ECOG performance status 0-4 - Histologically or cytology confirmed NSCLC - Documented ALK rearrangement based on an EMA approved test - Patients can either be chemotherapy-naïve or have received one line of platinum-based chemotherapy - Patients with brain or leptomeningeal metastases are allowed on the study if the lesions are asymptomatic without neurological signs and clinically stable for at least 2 weeks without steroid treatment. Patients who do not meet these criteria are not eligible for the study - Measurable disease (by RECIST criteria version 1.1) prior to the first dose of study treatment - Signed writte Institutional Review Board (IRB)/Ethical Committee (EC) approved informed consent form, prior to performing any study-related procedures - Observational other studies are allwoed for patients included in this study - Local radiotherapy is allowed for pain Exclusion Criteria: - Any significant concomitant disease determined by the investigator to be potentially aggravated by the investigational drug - Consumption of agents which modulate CYP3A4 or agents with potential QT prolonging effects within 14 days prior to admission and during the study (see concomitant medication restrictions) - Any clinically significant concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study, or absorption of oral medications, or that would, in the opinion of the Principal Investigator, pose an unacceptable risk to the subject in this study. - Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol requirements and/or follow-up procedures; those conditions should be discussed with the patient before trial entry.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Alectinib
In case of an alectinib plasmaconcentration Cmin <435 ng/mL, determined by TDM, and manageable toxicity, the alectinib dose will be increased with 150mg BID up to a maximum of 900mg BID. In case of unacceptable toxicity (i.e. unbearable or persistent grade 2 toxicity and grade 3/4 toxicity), the alectinib dose can be reduced by 150mg BID.

Locations

Country Name City State
France Gustave Roussy Villejuif Val-de-Marne
Netherlands Amsterdam University Medical Center Amsterdam Noord-Holland
Netherlands The Netherlands Cancer Institute Amsterdam Noord-Holland
Netherlands University Medical Center Groningen Groningen
Netherlands Leiden University Medical Center Leiden Zuid-Holland
Netherlands Maastricht University Medical Center + Maastricht Limburg
Netherlands Radboud University Medical Center Nijmegen Gelderland
Netherlands Erasmus Medical Center Rotterdam Zuid-Holland

Sponsors (7)

Lead Sponsor Collaborator
University Medical Center Groningen Amsterdam University Medical Center, Erasmus Medical Center, Leiden University Medical Center, Maastricht University Medical Center, Radboud University Medical Center, The Netherlands Cancer Institute

Countries where clinical trial is conducted

France,  Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Median progression free survival (mPFS) PFS is measured from start of treatment to progressive disease, death or lost to follow-up.Patients who did not die or progress, or lost to follow-up, will be censored at their last available date. mPFS will be assessed through study completion, after 12 months of follow-up.
Secondary Succesfull Therapeutic Drug monitoring The percentage of succesfull TDM interventions, in which successful is defines as tartget attainment and manageable toxicity. 4 to 6 weeks after dose adjustment based on TDM
Secondary Overall response rate (ORR) ORR is the percentage of patients with partial response or complete response, according to RECIST v1.1, of the total treated population. Response will be assessed every 2-3 months. ORR will be determined after total study completion and 12 months of follow-up
Secondary Median overall survival mOS is defined as time from randomization to death from any cause in the total population. Through total study completion, after 12 months of follow-up
Secondary Intracranial PFS PFS is measured from start of treatment to progressive disease in the brain, death or lost to follow-up. Patients who did not die or progress, or lost to follow-up, will be censored at their last available date. Progressive disease will be assessed once every 2-3 months. Intracranial PFS will be assessed through total study completion, after 12 months of follow-up
Secondary Patient adherence to alectinib treatment This will be estimated by pill counts of returned medication as well as a patient diary on drug intake. Through study completion, an average of 2 years
Secondary Number of adverse events (AE) related to plasma concentration and dose increases AE's will be defined using CTCAE v5.0. Number of AE's in the subgroups of patients with Cmin <435 ng/mL compared to Cmin >= 435 ng/ML, and in patients who did and who did not receive a TDM-guided dose increase. Through total study completion, after 12 months of follow-up
Secondary European Organization for Research and Treatment of Cancer 30-item core quality of life questionnaire (EORTC QLQ-C30) and the the Quality of Life Questionnaire-Lung Cancer 13 (EORTC QLQ-LC-13) module Mean change from baseline in EORTC QLQ-C30 and QLQ-LC13 scores Questionnaires will be filled in at baseline and every 3 months thereafter through study completion, an average of 2 years.
Secondary European Quality of Life Five Dimensions with five levels (EQ-5D-5L) questionnaire Mean change from baseline in EQ-5D-5L score Questionnaire will be filled in at baseline and every 3 months thereafter through study completion, an average of 2 years.
Secondary Incremental cost-effectiveness ratio (ICER) The ICER is the final outcome of the comparative cost-effectiveness analysis performed using a health-state transition model to compare costs and effectiveness between both study arms. Through total study completion, after 12 months of follow-up
Secondary Alectinib M4 protein Alectinib M4 plasmaconcentrations in relation to alectinib plasma concentrations Through total study completion, after 12 months of follow-up
See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk